Popular on TelAve
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- TCAA Welcomes Adolfo Gomez Sanchez to Its Family of Talented Speakers
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
Similar on TelAve
- Pixel Studio Productions Launches Same-Day Headshots in Houston
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
TelAve News/10848545
Mental health watchdog launches new campaign to obtain "zero tolerance" for the psychotropic drugging of children, some too young to even walk
LOS ANGELES - TelAve -- In commemoration of Universal Children's Day in November and Human Rights Day on December 10th, the Citizens Commission on Human Rights International launched a new campaign in the U.S. aimed at securing legislative and policymaker support for a zero-tolerance approach to psychotropic drugging of children. CCHR is deeply concerned by the 6.1 million children in America prescribed psychotropic drugs in 2020, including 418,425 in the 0–5 age group. The group obtained this data from IQVIA (formerly IMS Health), the largest vendor of U.S. physician prescribing data. While these alarming figures reflect the broader scope of psychotropic drugging, government programs such as Medicaid and Children's Health Insurance Program (CHIP) are funding what CCHR deems "child abuse" as infants, toddlers and preschoolers are subjected to powerful drugs that can pose serious, long-term risks to their health and development.
In 2023, 6.5 million Medicaid/Children's Health Insurance Program (CHIP) beneficiaries were ages 0-2 and a further 20.6 million were aged 3-11. CCHR says there needs to be a massive overhaul of Medicaid and CHIP, which has become a lucrative system for those prescribing mind-altering drugs to millions of children—some so powerful they can drive them to suicide and acts of violence. Medicaid and CHIP are the largest payers for mental health services and substance abuse treatment.[1]
CCHR wants to see the adoption of policies similar to those in the United Kingdom to start reducing the drugging of children. In the UK, a group of about 30 medical experts and politicians discovered "Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen." They called for a reversal in the rate of antidepressant prescribing (de-prescribing) which includes, stopping the prescribing of antidepressants for mild conditions for new patients, proper informed consent and regular review of harms, as well as funding and delivering a national 24-hour prescribed drug withdrawal helpline and website.[2]
More on TelAve News
The group says that policies must encompass all psychotropic drugs. Medicaid administration programs have attempted to address the massive prescribing of antipsychotics and other psychotropics in children and adolescents, particularly foster care youth, following government reports highlighting excessive use. Consequently, some state Medicaid oversight programs have published research indicating a reduction in antipsychotic use among children, according to Julie Zito, a professor of Pharmacy and Psychiatry at the University of Maryland, and her colleagues in Frontiers in Psychiatry.[3] However, CCHR questions the accuracy of these reduction claims.
In 2023, a study published in Health Affairs did show there was a sizeable 43% decline in antipsychotic use among children aged 2–17 under Medicaid between 2008 and 2016. The largest absolute decline was observed in White children (−1.37%) vs. Black (−0.62%), Hispanic (−0.31%), and Asian (−0.17%) children.[4]
However, for children in foster care, antipsychotic use was still overrepresented. Although slightly decreased, in 2016, 7.7% were prescribed the drugs compared to 1.19% not in foster care. The researchers warned that antipsychotics are associated with potentially serious side effects, including type 2 diabetes, cardiometabolic effects (such as high blood pressure, weight gain, cholesterol problems, etc.), and unexpected death.
Antipsychotics have consistently ranked among the top drug classes for Medicaid spending across all age groups. In 2019, psychotherapeutic agents—including antipsychotics and antidepressants—were the third most expensive outpatient drug class for the program. That year, antipsychotics represented 9% of Medicaid's total spending ($6.2 billion) and 10% of all prescriptions (73.1 million claims). Between 2016 and 2021, the total number of antipsychotic prescription claims rose by 23.3% from 18.5 million. Similarly, total gross spending on these drugs increased by 16.7%, climbing from $5.17 billion in 2016 to $6.03 billion in 2021.[5]
Children in the welfare system are also a target for these drugs. A 2023 study published in JAMA Pediatrics analyzed the prevalence of psychotropic drug use and polypharmacy—the practice of prescribing two or more drugs—among Medicaid beneficiaries and children in the child welfare system. This latter group included youth accessing adoption assistance, foster care, or guardianship care.
More on TelAve News
Researchers estimated the rates of psychotropic drug use, polypharmacy, and associated mental health conditions by age group (3-17, 3-5, 6-11, and 12-17 years)."
Findings revealed that 26.25% of children in the child welfare group had been prescribed at least one psychotropic drug, and 13.27% experienced polypharmacy. By comparison, 9.06% of other Medicaid-enrolled youths were prescribed psychotropic drugs, with only 3.11% experiencing polypharmacy.
The most common class of psychotropic drugs in the child welfare group was stimulants (15.95%), followed by antidepressants (9.88%) and antipsychotics (7.87%).[6]
Psychotropic polypharmacy also affects substantially more children and adolescents today than has been the case, Julie Zito, Ph.D. reported. As many as 300,000 youth now receive three or more classes concomitantly. The duration of concomitant use is relatively long, e.g., 69–89% of annual medicated days. More adverse event reports are associated with 3-class compared with 2-class drug regimens.[7]
Supporting a zero-tolerance de-escalation policy should include warning parents and caregivers of children in the welfare and Medicaid-CHIP populations about the critical adverse drug effects. This information is concisely presented in FDA-approved Medication Guides—handouts provided with many prescriptions—designed to help consumers recognize and avoid serious adverse events.
Both state and federal governments are urged to adopt a strong policy of "de-prescribing" powerful psychotropic drugs to children and adolescents.
By prioritizing these measures, the U.S. can take significant steps toward safeguarding the well-being of its youngest and most vulnerable populations, protecting them from harmful psychotropic drugs.
Sources:
[1] www.medicaid.gov/medicaid/quality-of-care/downloads/beneficiary-ataglance-2023.pdf
[2] www.bmj.com/content/383/bmj.p2730
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
[4] pmc.ncbi.nlm.nih.gov/articles/PMC10845053/
[5] link.springer.com/article/10.1007/s11414-024-09889-0
[6] pmc.ncbi.nlm.nih.gov/articles/PMC10442784/
[7] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
In 2023, 6.5 million Medicaid/Children's Health Insurance Program (CHIP) beneficiaries were ages 0-2 and a further 20.6 million were aged 3-11. CCHR says there needs to be a massive overhaul of Medicaid and CHIP, which has become a lucrative system for those prescribing mind-altering drugs to millions of children—some so powerful they can drive them to suicide and acts of violence. Medicaid and CHIP are the largest payers for mental health services and substance abuse treatment.[1]
CCHR wants to see the adoption of policies similar to those in the United Kingdom to start reducing the drugging of children. In the UK, a group of about 30 medical experts and politicians discovered "Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen." They called for a reversal in the rate of antidepressant prescribing (de-prescribing) which includes, stopping the prescribing of antidepressants for mild conditions for new patients, proper informed consent and regular review of harms, as well as funding and delivering a national 24-hour prescribed drug withdrawal helpline and website.[2]
More on TelAve News
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
The group says that policies must encompass all psychotropic drugs. Medicaid administration programs have attempted to address the massive prescribing of antipsychotics and other psychotropics in children and adolescents, particularly foster care youth, following government reports highlighting excessive use. Consequently, some state Medicaid oversight programs have published research indicating a reduction in antipsychotic use among children, according to Julie Zito, a professor of Pharmacy and Psychiatry at the University of Maryland, and her colleagues in Frontiers in Psychiatry.[3] However, CCHR questions the accuracy of these reduction claims.
In 2023, a study published in Health Affairs did show there was a sizeable 43% decline in antipsychotic use among children aged 2–17 under Medicaid between 2008 and 2016. The largest absolute decline was observed in White children (−1.37%) vs. Black (−0.62%), Hispanic (−0.31%), and Asian (−0.17%) children.[4]
However, for children in foster care, antipsychotic use was still overrepresented. Although slightly decreased, in 2016, 7.7% were prescribed the drugs compared to 1.19% not in foster care. The researchers warned that antipsychotics are associated with potentially serious side effects, including type 2 diabetes, cardiometabolic effects (such as high blood pressure, weight gain, cholesterol problems, etc.), and unexpected death.
Antipsychotics have consistently ranked among the top drug classes for Medicaid spending across all age groups. In 2019, psychotherapeutic agents—including antipsychotics and antidepressants—were the third most expensive outpatient drug class for the program. That year, antipsychotics represented 9% of Medicaid's total spending ($6.2 billion) and 10% of all prescriptions (73.1 million claims). Between 2016 and 2021, the total number of antipsychotic prescription claims rose by 23.3% from 18.5 million. Similarly, total gross spending on these drugs increased by 16.7%, climbing from $5.17 billion in 2016 to $6.03 billion in 2021.[5]
Children in the welfare system are also a target for these drugs. A 2023 study published in JAMA Pediatrics analyzed the prevalence of psychotropic drug use and polypharmacy—the practice of prescribing two or more drugs—among Medicaid beneficiaries and children in the child welfare system. This latter group included youth accessing adoption assistance, foster care, or guardianship care.
More on TelAve News
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Nonprofit innovator named Mensa Executive Director
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- Chasing Elizabeth Taylor — The Dazzling True Story Behind the Queen of Diamonds Now Available in Limited-Edition Hardcover
Researchers estimated the rates of psychotropic drug use, polypharmacy, and associated mental health conditions by age group (3-17, 3-5, 6-11, and 12-17 years)."
Findings revealed that 26.25% of children in the child welfare group had been prescribed at least one psychotropic drug, and 13.27% experienced polypharmacy. By comparison, 9.06% of other Medicaid-enrolled youths were prescribed psychotropic drugs, with only 3.11% experiencing polypharmacy.
The most common class of psychotropic drugs in the child welfare group was stimulants (15.95%), followed by antidepressants (9.88%) and antipsychotics (7.87%).[6]
Psychotropic polypharmacy also affects substantially more children and adolescents today than has been the case, Julie Zito, Ph.D. reported. As many as 300,000 youth now receive three or more classes concomitantly. The duration of concomitant use is relatively long, e.g., 69–89% of annual medicated days. More adverse event reports are associated with 3-class compared with 2-class drug regimens.[7]
Supporting a zero-tolerance de-escalation policy should include warning parents and caregivers of children in the welfare and Medicaid-CHIP populations about the critical adverse drug effects. This information is concisely presented in FDA-approved Medication Guides—handouts provided with many prescriptions—designed to help consumers recognize and avoid serious adverse events.
Both state and federal governments are urged to adopt a strong policy of "de-prescribing" powerful psychotropic drugs to children and adolescents.
By prioritizing these measures, the U.S. can take significant steps toward safeguarding the well-being of its youngest and most vulnerable populations, protecting them from harmful psychotropic drugs.
Sources:
[1] www.medicaid.gov/medicaid/quality-of-care/downloads/beneficiary-ataglance-2023.pdf
[2] www.bmj.com/content/383/bmj.p2730
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
[4] pmc.ncbi.nlm.nih.gov/articles/PMC10845053/
[5] link.springer.com/article/10.1007/s11414-024-09889-0
[6] pmc.ncbi.nlm.nih.gov/articles/PMC10442784/
[7] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
Source: Citizens Commission on Human Rights
0 Comments
Latest on TelAve News
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Cellhire boosts its EE offering via deal with BT Wholesale's Complete Mobile
- 24/7 customizable AI answering service from Kell Web Solutions, Inc. helps businesses never miss a customer call, lead, or appointment again
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety